| Item Type | Name |
|
Concept
|
Adenine
|
|
Concept
|
Albumins
|
|
Concept
|
Acid Phosphatase
|
|
Concept
|
Antigens, Neoplasm
|
|
Concept
|
Antibiotics, Antineoplastic
|
|
Concept
|
Aldosterone
|
|
Concept
|
Alkaline Phosphatase
|
|
Concept
|
Androstenols
|
|
Concept
|
Acrylamides
|
|
Concept
|
Acetaminophen
|
|
Concept
|
Alanine
|
|
Concept
|
Transaminases
|
|
Concept
|
Analgesics, Opioid
|
|
Concept
|
Adrenocorticotropic Hormone
|
|
Concept
|
Alcohol Dehydrogenase
|
|
Concept
|
Acetyltransferases
|
|
Concept
|
Aerosols
|
|
Concept
|
Anticonvulsants
|
|
Concept
|
Antigens, Surface
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Arylamine N-Acetyltransferase
|
|
Concept
|
Busulfan
|
|
Concept
|
Carbazoles
|
|
Concept
|
Aminopyridines
|
|
Concept
|
Analgesics
|
|
Concept
|
Androstadienes
|
|
Concept
|
Androstenes
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Antifungal Agents
|
|
Concept
|
Anthraquinones
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Aminoquinolines
|
|
Concept
|
Antihypertensive Agents
|
|
Concept
|
Anesthetics
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
|
Concept
|
Codeine
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Antidotes
|
|
Concept
|
Aryl Hydrocarbon Hydroxylases
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzamides
|
|
Concept
|
Carmustine
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Dipeptides
|
|
Concept
|
Azacitidine
|
|
Concept
|
Benzofurans
|
|
Concept
|
Drug Packaging
|
|
Concept
|
Bilirubin
|
|
Concept
|
Bleomycin
|
|
Concept
|
Biological Products
|
|
Concept
|
Complement System Proteins
|
|
Concept
|
Carbon Radioisotopes
|
|
Concept
|
Flavonoids
|
|
Concept
|
Floxuridine
|
|
Concept
|
Genetic Vectors
|
|
Concept
|
Chromium
|
|
Concept
|
Cisplatin
|
|
Concept
|
Leucovorin
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Caffeine
|
|
Concept
|
Glutathione Transferase
|
|
Concept
|
Creatinine
|
|
Concept
|
Hemoglobins
|
|
Concept
|
Collagen
|
|
Concept
|
Contrast Media
|
|
Concept
|
Dacarbazine
|
|
Concept
|
Cosyntropin
|
|
Concept
|
Hydroxyurea
|
|
Concept
|
Hymecromone
|
|
Concept
|
Imidazoles
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Dexamethasone
|
|
Concept
|
Drug Industry
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Cytidine Deaminase
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Drug Evaluation
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Drug Hypersensitivity
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Cyclohexanecarboxylic Acids
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Daunorubicin
|
|
Concept
|
Dehydroepiandrosterone
|
|
Concept
|
Ferredoxin-NADP Reductase
|
|
Concept
|
Tegafur
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Hemoglobin A
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Exons
|
|
Concept
|
Erythropoietin
|
|
Concept
|
Etoposide
|
|
Concept
|
Coformycin
|
|
Concept
|
Cytarabine
|
|
Concept
|
DNA Topoisomerases, Type II
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Drug Stability
|
|
Concept
|
Drug Utilization
|
|
Concept
|
Diphtheria Toxin
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Food
|
|
Concept
|
Indicators and Reagents
|
|
Concept
|
Indoles
|
|
Concept
|
Interferons
|
|
Concept
|
Introns
|
|
Concept
|
Methyltransferases
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Deoxyadenosines
|
|
Concept
|
Formaldehyde
|
|
Concept
|
Furans
|
|
Concept
|
DNA Topoisomerases, Type I
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Combinations
|
|
Concept
|
Drug Labeling
|
|
Concept
|
Pharmaceutical Preparations
|
|
Concept
|
Hydralazine
|
|
Concept
|
Liposomes
|
|
Concept
|
Enzymes
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Hydroxamic Acids
|
|
Concept
|
Hypnotics and Sedatives
|
|
Concept
|
Intercalating Agents
|
|
Concept
|
Isoenzymes
|
|
Concept
|
Glutathione
|
|
Concept
|
Lactones
|
|
Concept
|
Heterocyclic Compounds, 4 or More Rings
|
|
Concept
|
Maytansine
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Metformin
|
|
Concept
|
Hydroxytestosterones
|
|
Concept
|
Microfilament Proteins
|
|
Concept
|
Midazolam
|
|
Concept
|
Nogalamycin
|
|
Concept
|
Estrogen Antagonists
|
|
Concept
|
Exodeoxyribonucleases
|
|
Concept
|
Imides
|
|
Concept
|
Indazoles
|
|
Concept
|
Organoplatinum Compounds
|
|
Concept
|
Oxidoreductases, N-Demethylating
|
|
Concept
|
Meperidine
|
|
Concept
|
Methotrexate
|
|
Concept
|
Receptors, Estrogen
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Peptide Fragments
|
|
Concept
|
Nitriles
|
|
Concept
|
Phosphorylcholine
|
|
Concept
|
Oxidoreductases
|
|
Concept
|
Ligands
|
|
Concept
|
Safety
|
|
Concept
|
Oxycodone
|
|
Concept
|
Pentoxifylline
|
|
Concept
|
Melphalan
|
|
Concept
|
Phosphoproteins
|
|
Concept
|
Phenylurea Compounds
|
|
Concept
|
Morpholines
|
|
Concept
|
Nitrosamines
|
|
Concept
|
Phenobarbital
|
|
Concept
|
Drug Prescriptions
|
|
Concept
|
Prednisone
|
|
Concept
|
Epoprostenol
|
|
Concept
|
Piperazines
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Protease Inhibitors
|
|
Concept
|
Pyrazines
|
|
Concept
|
Pyridines
|
|
Concept
|
Mixed Function Oxygenases
|
|
Concept
|
Transcription Factors
|
|
Concept
|
Troleandomycin
|
|
Concept
|
Triazines
|
|
Concept
|
Idoxuridine
|
|
Concept
|
Imipramine
|
|
Concept
|
Guanine
|
|
Concept
|
Reference Standards
|
|
Concept
|
Verapamil
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Pyrrolidines
|
|
Concept
|
Quinoxalines
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Ribonucleosides
|
|
Concept
|
Drugs, Investigational
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Lactams
|
|
Concept
|
Thiotepa
|
|
Concept
|
Thymidine
|
|
Concept
|
Sulfonic Acids
|
|
Concept
|
Complement C1q
|
|
Concept
|
Thalidomide
|
|
Concept
|
Interferon Type I
|
|
Concept
|
Tetrahydrofolates
|
|
Concept
|
Thiones
|
|
Concept
|
Thionucleotides
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Succinylcholine
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Uridine Diphosphate
|
|
Concept
|
Receptors, IgG
|
|
Concept
|
Warfarin
|
|
Concept
|
Tamoxifen
|
|
Concept
|
Thiophenes
|
|
Concept
|
Vasodilator Agents
|
|
Concept
|
Drug Design
|
|
Concept
|
Isoquinolines
|
|
Concept
|
Ketoconazole
|
|
Concept
|
Isotretinoin
|
|
Concept
|
Mercaptopurine
|
|
Concept
|
Sulfotransferases
|
|
Concept
|
Thyroxine
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
CD56 Antigen
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Myeloablative Agonists
|
|
Concept
|
Receptors, Interleukin-6
|
|
Concept
|
Oligodeoxyribonucleotides, Antisense
|
|
Concept
|
Glucuronic Acid
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Vinca Alkaloids
|
|
Concept
|
Vitamins
|
|
Concept
|
Carboplatin
|
|
Concept
|
Myosin Type II
|
|
Concept
|
Propofol
|
|
Concept
|
Arylsulfotransferase
|
|
Concept
|
Quinolones
|
|
Concept
|
DNA, Antisense
|
|
Concept
|
Mephenytoin
|
|
Concept
|
Receptors, Interleukin-2
|
|
Concept
|
Pentostatin
|
|
Concept
|
2-Chloroadenosine
|
|
Concept
|
Drug Costs
|
|
Concept
|
Fluvoxamine
|
|
Concept
|
Morphine
|
|
Concept
|
Xenobiotics
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Drug Approval
|
|
Concept
|
Drug Delivery Systems
|
|
Concept
|
Alternative Splicing
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Receptors, Endothelin
|
|
Concept
|
Mycophenolic Acid
|
|
Concept
|
Dihydrouracil Dehydrogenase (NADP)
|
|
Concept
|
Oligodeoxyribonucleotides
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Nedocromil
|
|
Concept
|
Receptors, Cytoplasmic and Nuclear
|
|
Concept
|
Platinum Compounds
|
|
Concept
|
Receptors, Growth Factor
|
|
Concept
|
DNA, Complementary
|
|
Concept
|
Dinucleotide Repeats
|
|
Concept
|
ras Proteins
|
|
Concept
|
Hepatocyte Nuclear Factor 1-alpha
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2D6
|
|
Concept
|
Kv1.3 Potassium Channel
|
|
Concept
|
Cyclohexenes
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Alkyl and Aryl Transferases
|
|
Concept
|
Multidrug Resistance-Associated Proteins
|
|
Concept
|
Analgesics, Non-Narcotic
|
|
Concept
|
Drug Dosage Calculations
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Myosin Heavy Chains
|
|
Concept
|
Cladribine
|
|
Concept
|
Collagen Type I
|
|
Concept
|
Topoisomerase I Inhibitors
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Endostatins
|
|
Concept
|
Receptors, G-Protein-Coupled
|
|
Concept
|
Equilibrative Nucleoside Transporter 1
|
|
Concept
|
Epothilones
|
|
Concept
|
Herb-Drug Interactions
|
|
Concept
|
Methylenetetrahydrofolate Reductase (NADPH2)
|
|
Concept
|
Hepatocyte Nuclear Factor 1
|
|
Concept
|
Lactams, Macrocyclic
|
|
Concept
|
Megestrol Acetate
|
|
Concept
|
Budesonide
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
3' Untranslated Regions
|
|
Concept
|
RecQ Helicases
|
|
Concept
|
Glucuronides
|
|
Concept
|
Sirolimus
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Proto-Oncogene Proteins c-ret
|
|
Concept
|
Phosphotransferases
|
|
Concept
|
Phthalazines
|
|
Concept
|
Phenylenediamines
|
|
Concept
|
Platinum
|
|
Concept
|
Podophyllotoxin
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Piperidines
|
|
Concept
|
Organic Anion Transporters, Sodium-Independent
|
|
Concept
|
Prodrugs
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Pyrimidines
|
|
Concept
|
Quinazolines
|
|
Concept
|
Recombinant Proteins
|
|
Concept
|
Pyrroles
|
|
Concept
|
Serum Albumin
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Snake Venoms
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Testosterone
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Taxoids
|
|
Concept
|
Pyrazolones
|
|
Concept
|
Luciferases, Firefly
|
|
Concept
|
Triazoles
|
|
Concept
|
Prescription Drugs
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
TOR Serine-Threonine Kinases
|
|
Concept
|
Adenosine A2 Receptor Antagonists
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Uracil
|
|
Concept
|
Stereoisomerism
|
|
Concept
|
Valproic Acid
|
|
Concept
|
Vincristine
|
|
Concept
|
Vitamin D
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Suramin
|
|
Concept
|
Epirubicin
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
|
Concept
|
NFATC Transcription Factors
|
|
Concept
|
Thiosemicarbazones
|
|
Concept
|
Thymidylate Synthase
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
Vinblastine
|
|
Concept
|
Zidovudine
|
|
Concept
|
Topoisomerase Inhibitors
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
ATP-Binding Cassette Transporters
|
|
Concept
|
Food-Drug Interactions
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Cyclin-Dependent Kinases
|
|
Concept
|
Menogaril
|
|
Concept
|
HIV Protease Inhibitors
|
|
Concept
|
Naphthalimides
|
|
Concept
|
Ritonavir
|
|
Concept
|
Indinavir
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Interleukin-17
|
|
Concept
|
Receptors, Calcitriol
|
|
Concept
|
HSP90 Heat-Shock Proteins
|
|
Concept
|
Histone Deacetylase Inhibitors
|
|
Concept
|
Topotecan
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
O(6)-Methylguanine-DNA Methyltransferase
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Receptor, trkA
|
|
Concept
|
Receptor, EphA5
|
|
Concept
|
Aldehyde Oxidase
|
|
Concept
|
Organic Anion Transporters
|
|
Concept
|
Tubulin Modulators
|
|
Concept
|
Janus Kinase 2
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Depsipeptides
|
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Protein Kinase C-alpha
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Topoisomerase II Inhibitors
|
|
Concept
|
Aldehyde Dehydrogenase
|
|
Concept
|
Anilides
|
|
Concept
|
Anthracenes
|
|
Concept
|
Immunotoxins
|
|
Concept
|
Hypolipidemic Agents
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Benzenesulfonates
|
|
Concept
|
Camptothecin
|
|
Concept
|
Capsules
|
|
Concept
|
Carbolines
|
|
Concept
|
Cardiovascular Agents
|
|
Concept
|
Carrier Proteins
|
|
Concept
|
Catechin
|
|
Concept
|
Catechol O-Methyltransferase
|
|
Concept
|
Chlorambucil
|
|
Concept
|
Cytosine
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Dietary Fats
|
|
Concept
|
Dioxolanes
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Drug Screening Assays, Antitumor
|
|
Concept
|
Glucuronates
|
|
Concept
|
Indenes
|
|
Concept
|
Morphine Derivatives
|
|
Concept
|
Naphthyridines
|
|
Concept
|
Neoplasm Proteins
|
|
Concept
|
Niacinamide
|
|
Concept
|
Nicotine
|
|
Concept
|
Nitrophenols
|
|
Concept
|
Oligonucleotides
|
|
Concept
|
Omeprazole
|
|
Concept
|
Orphan Drug Production
|
|
Concept
|
Peptides
|
|
Concept
|
Platelet Aggregation Inhibitors
|
|
Concept
|
Recombinant Fusion Proteins
|
|
Concept
|
Serine Endopeptidases
|
|
Concept
|
Thymine
|
|
Concept
|
Tramadol
|
|
Concept
|
Glucuronosyltransferase
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Oligonucleotides, Antisense
|
|
Concept
|
Anticarcinogenic Agents
|
|
Concept
|
DNA Primers
|
|
Concept
|
Anti-Asthmatic Agents
|
|
Concept
|
Macrolides
|
|
Concept
|
Membrane Transport Proteins
|
|
Concept
|
Organic Cation Transporter 1
|
|
Concept
|
Plant Preparations
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Transforming Growth Factor beta3
|
|
Concept
|
Drug Recalls
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
|
Academic Article
|
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
|
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
|
Academic Article
|
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Individualizing dosing of cancer chemotherapy.
|
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
|
Academic Article
|
Mineralocorticoid insufficiency due to suramin therapy.
|
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
|
Academic Article
|
New phase I trial methodology.
|
|
Academic Article
|
Suramin: is adaptive control necessary?
|
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Promising new agents in oncologic treatment.
|
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
|
Academic Article
|
Development of target-based antineoplastic agents.
|
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
|
Academic Article
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
|
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
|
Academic Article
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
|
Academic Article
|
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
|
Academic Article
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
|
Academic Article
|
Elimination pathways of [14C]losoxantrone in four cancer patients.
|
|
Academic Article
|
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
|
|
Academic Article
|
Anticancer drug discovery and development throughout the world.
|
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
|
Academic Article
|
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
|
|
Academic Article
|
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
|
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
|
Academic Article
|
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
|
|
Academic Article
|
Personalized medicine: building the GPS to take us there.
|
|
Academic Article
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
|
|
Academic Article
|
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
|
|
Academic Article
|
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
|
|
Academic Article
|
Finding the right dose.
|
|
Academic Article
|
Pharmacogenomics: challenges and opportunities.
|
|
Academic Article
|
Irinogenetics: what is the right star?
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
|
Academic Article
|
Effects of green tea compounds on irinotecan metabolism.
|
|
Academic Article
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
|
Academic Article
|
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
|
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
|
Academic Article
|
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
|
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
|
Academic Article
|
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
|
|
Academic Article
|
Biomarkers in early cancer drug development: limited utility.
|
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
|
Academic Article
|
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
|
|
Academic Article
|
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
|
|
Academic Article
|
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
|
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
|
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
|
Academic Article
|
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
|
|
Academic Article
|
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
|
|
Academic Article
|
The investigational drug steering committee.
|
|
Academic Article
|
Flushing oral oncology drugs down the toilet.
|
|
Academic Article
|
Models of excellence: improving oncology drug development.
|
|
Academic Article
|
Why RECIST works and why it should stay--reply to counterpoint.
|
|
Academic Article
|
Nonprofit biomedical companies.
|
|
Academic Article
|
Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.
|
|
Academic Article
|
Phase I and pharmacological study of vinblastine by prolonged continuous infusion.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
|
Academic Article
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
|
Academic Article
|
Importance of food effects for oral oncology drugs.
|
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
|
Academic Article
|
Cancer chemotherapy and skin changes.
|
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
|
Academic Article
|
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
|
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
|
Academic Article
|
Limited sampling model for vinblastine pharmacokinetics.
|
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
|
Academic Article
|
Individualizing dosing of irinotecan.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
|
|
Academic Article
|
Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.
|
|
Academic Article
|
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
|
|
Academic Article
|
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
|
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
|
|
Academic Article
|
The role of pharmacogenetics in cancer therapeutics.
|
|
Academic Article
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Creating and evaluating genetic tests predictive of drug response.
|
|
Academic Article
|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
|
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
|
Academic Article
|
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Oncology micro-cap stocks: caveat emptor!
|
|
Academic Article
|
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
|
|
Academic Article
|
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
|
|
Academic Article
|
Playing Russian roulette with tyrosine kinase inhibitors.
|
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
|
Academic Article
|
Preventing adverse drug-drug interactions: a need for improved data and logistics.
|
|
Academic Article
|
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Are drug labels static or dynamic?
|
|
Academic Article
|
Unmet needs in preventing adverse drug-drug interactions.
|
|
Academic Article
|
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
|
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
|
Academic Article
|
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
|
Academic Article
|
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Disease-drug database for pharmacogenomic-based prescribing.
|
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
|
Academic Article
|
Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.
|
|
Academic Article
|
Drug-Drug Interactions With Oral Antineoplastic Agents.
|
|
Academic Article
|
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
|
|
Academic Article
|
Food Effect Studies for Oncology Drug Products.
|
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
|
Academic Article
|
Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781.
|
|
Academic Article
|
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies.
|
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
|
Academic Article
|
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
|
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
|
Academic Article
|
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.
|
|
Academic Article
|
The Role of Early-Phase Design-Letter.
|
|
Academic Article
|
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.
|
|
Academic Article
|
Pharmacogenomic considerations for medications in the perioperative setting.
|
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
|
Academic Article
|
Alternative dosing regimens for atezolizumab: right dose, wrong frequency.
|
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
|
Academic Article
|
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
|
|
Academic Article
|
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
|
|
Academic Article
|
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
|
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
|
Academic Article
|
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
|
|
Academic Article
|
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
|
|
Academic Article
|
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.
|
|
Academic Article
|
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
|
|
Academic Article
|
The Right Dose: From Phase I to Clinical Practice.
|
|
Academic Article
|
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
|
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
|
Academic Article
|
Subcutaneous Atezolizumab: A Jab Without a Benefit.
|
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
|
Academic Article
|
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.
|
|
Academic Article
|
Oncology Drug Prescribing: The Influences of Greed and Fear.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Academic Article
|
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
|
|
Concept
|
Organophosphonates
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Cytochrome P-450 CYP2C19
|
|
Concept
|
Cytochrome P-450 Enzyme Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2D6 Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP3A Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2B6
|
|
Concept
|
Cytochrome P-450 CYP2C8
|
|
Concept
|
Cytochrome P-450 CYP2C9
|
|
Concept
|
ErbB Receptors
|
|
Academic Article
|
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
|
|
Academic Article
|
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
|
|
Academic Article
|
Special designations and the US Food and Drug Administration's "dual mandate".
|
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
|
Academic Article
|
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer.
|